Browse the evidence

Discontinuation of obesity management medications (OMMs) such as tirzepatide or semaglutide leads to substantial weight regain and partial reversal of cardiometabolic improvements, indicating that sustained treatment is required to maintain health benefits.

If you stop taking your obesity medication (like tirzepatide or semaglutide), you will likely regain most of the weight you lost, even if you keep your diet and exercise habits. To keep the health benefits, you generally need to stay on the medication long-term.

Incretin-based therapies (GLP-1 and GIP/GLP-1 RAs) produce clinically significant weight loss and improve weight-related comorbidities, but their implementation is hindered by high costs, insurance coverage barriers, supply shortages, and gastrointestinal adverse events.

Incretin-based therapies like semaglutide and tirzepatide are highly effective for weight loss and improving health conditions like diabetes and heart disease. However, access is difficult due to high costs, insurance restrictions, and supply shortages. Side effects like nausea are common but often improve over time. Patients should work with pharmacists to navigate coverage and manage side effects through careful dosing.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, while also reducing liver fat content and improving liver enzymes in those with MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to significantly lower your risk of heart failure and death, and they also help reduce fat in your liver. They are a key part of modern care for this condition.

GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) and promote histological resolution of MASH in patients with T2D and MASLD.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about GLP-1 receptor agonists (like semaglutide or liraglutide). These drugs are proven to significantly lower your risk of heart attacks and strokes, and they can even reverse liver inflammation (MASH) in some patients. They are a key part of modern care for this condition.

GLP-1 receptor agonists (GLP-1 RAs) produce modest but statistically significant reductions in systolic blood pressure (SBP) in patients with type 2 diabetes and/or obesity, primarily through weight loss, improved endothelial function, and renal sodium excretion.

If you have type 2 diabetes or obesity, GLP-1 medications like semaglutide or liraglutide can help lower your blood pressure slightly. However, they are not strong enough to replace your blood pressure medication if your numbers are high. The real value is that they help with weight and blood sugar at the same time. Talk to your doctor about whether the added benefits outweigh the cost and potential stomach side effects.

Tirzepatide reduces major adverse cardiovascular events (MACE), including acute myocardial infarction and all-cause mortality, in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes, Tirzepatide offers significant cardiovascular protection, reducing the risk of heart attack, stroke, and death by approximately 40% compared to other GLP-1 agonists. This makes it a preferred choice for patients with high cardiovascular risk.

GLP-1 receptor agonists (GLP-1RAs) provide cardiovascular protection by reducing systemic inflammation, improving endothelial function, and reducing epicardial adipose tissue (EAT) volume, independent of weight loss.

If you have Type 2 Diabetes or Obesity, GLP-1 receptor agonists (like Ozempic, Wegovy, or Victoza) offer heart protection beyond just weight loss. They reduce inflammation in your blood vessels and shrink fat around your heart (EAT), which lowers your risk of heart disease. This benefit happens even if you don't lose a huge amount of weight. Talk to your doctor about whether these medications are right for your cardiovascular health.

Tirzepatide and Mazdutide, as dual-receptor agonists, offer superior glucose-lowering and weight loss efficacy compared to conventional GLP-1RAs, but their high cost and lack of reimbursement limit their overall recommendation status.

Tirzepatide and Mazdutide are powerful dual-receptor agonists that offer superior glucose and weight loss benefits compared to conventional GLP-1RAs. However, their high cost and lack of insurance coverage in China make them less accessible. Patients should discuss these options with their doctors, considering both efficacy and affordability. If cost is a barrier, Semaglutide and Dulaglutide are strong alternatives with established cardiovascular benefits.

Micellar casein provides a sustained, slow-release amino acid profile, whereas free L-amino acids (L-AAs) and casein glycomacropeptide (CGMP) result in rapid, transient absorption peaks.

If you want a slow, steady drip of amino acids (like before bed or during long fasting windows), choose micellar casein. If you need a rapid spike of amino acids (like immediately post-workout), free amino acids or CGMP will deliver them much faster than casein. Note that CGMP does not act like casein despite being a peptide.

Visceral adipose tissue (VAT) accumulation exacerbates insulin resistance and increases fasting blood glucose and HbA1c, whereas brown adipose tissue (BAT) activation improves glucose regulation and insulin sensitivity.

Focus on reducing visceral fat (belly fat) rather than just total body weight. Strategies that activate brown fat (like cold exposure or specific exercises) or reduce visceral fat (through diet/exercise) are more effective for blood sugar control than general weight loss alone.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.

Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists significantly reduce major adverse cardiovascular events (MACE), with weight loss acting as the predominant mediator of this benefit compared to blood pressure reduction alone.

If you have type 2 diabetes or obesity and are at high cardiovascular risk, GLP-1RA medications can significantly lower your risk of heart attacks and strokes. The benefit comes largely from the weight loss these drugs cause, rather than just lowering blood pressure. Discuss these options with your doctor, especially if you have resistant hypertension.

Using ambulatory blood pressure monitoring (ABPM) instead of clinic-based measurements reveals a stronger and more consistent cardiovascular benefit from GLP-1RA therapy.

If you are on GLP-1RA therapy, ask your doctor about using ambulatory blood pressure monitoring (ABPM). It may provide a more accurate assessment of your cardiovascular risk and the effectiveness of your treatment compared to standard clinic blood pressure readings.

Higher baseline insulin sensitivity is associated with greater retention of lean mass during diet-induced weight loss, but this protective effect is nullified when aerobic or resistance exercise is included in the intervention.

If you are losing weight through diet alone, your metabolic health (insulin sensitivity) dictates how much muscle you keep; those with better sensitivity lose less muscle. However, if you add exercise (especially resistance training), your baseline insulin sensitivity no longer matters for muscle preservation. Exercise protects muscle mass regardless of your metabolic profile, making it the most reliable tool for preserving lean mass during weight loss.

Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.

Understand that GLP-1 therapy is likely a long-term commitment. If you stop taking the medication, you will likely regain most of the weight you lost. Plan for ongoing management rather than a fixed 'end date' for treatment.

Testosterone therapy (TTh) combined with GLP-1 receptor agonists (GLP-1RAs) and lifestyle modifications constitutes a comprehensive standard of care for obese men with functional hypogonadism, addressing metabolic, vascular, sexual, cognitive, and skeletal health.

For obese men with low testosterone, combining testosterone therapy with GLP-1RA medications (like semaglutide or liraglutide) and lifestyle changes (diet and exercise) is the most effective strategy. This approach not only boosts testosterone but also improves metabolic health, sexual function, and bone density, offering a comprehensive solution to obesity-related hormonal issues.

Dual incretin agonists (e.g., Tirzepatide) reduce total body fat mass and adipocyte size more effectively than selective GLP-1 receptor agonists (e.g., Semaglutide, Dulaglutide) by modulating both GLP-1 and GIP receptors, leading to enhanced lipolysis and reduced visceral fat.

If you are considering a dual incretin agonist like Tirzepatide, be aware that it targets two hormonal pathways (GLP-1 and GIP) rather than just one. This dual action leads to a significantly greater reduction in total body fat and visceral fat compared to single-target GLP-1 drugs, offering a more potent option for weight management.

Higher baseline circulating leptin levels in patients correlate with greater weight loss efficacy when treated with tirzepatide.

If you have obesity and type 2 diabetes, your baseline leptin level may predict how much weight you will lose with tirzepatide. Higher leptin levels are associated with greater weight loss, suggesting that combination therapy with leptin might be particularly beneficial for those with higher baseline levels.

GLP-1 receptor agonists (semaglutide 2.4 mg, tirzepatide) produce significantly greater weight loss than bariatric surgery in some metrics, but surgery remains superior for long-term durability and metabolic improvement, making GLP-1RAs a viable non-surgical alternative for patients who cannot or will not undergo surgery.

If you have obesity and want significant weight loss without surgery, ask your doctor about GLP-1 receptor agonists like semaglutide (2.4 mg weekly). These drugs work by slowing digestion and signaling fullness to your brain. They can lead to about 15% body weight loss over 16 months, which is substantial. Be prepared for potential nausea or digestive issues, which often improve over time. This is a medical treatment, not a quick fix, and works best when combined with lifestyle changes.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces the prevalence of metabolic syndrome by improving its core components: glycemic control, body weight, lipid profiles, and blood pressure.

If you have metabolic syndrome (high blood pressure, high blood sugar, high cholesterol, and excess belly fat), talk to your doctor about tirzepatide. It is a once-weekly injection that helps lower blood sugar, reduce weight, improve cholesterol, and lower blood pressure. While it can cause temporary stomach issues, these often go away, and it may offer a more comprehensive solution than lifestyle changes alone.

GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss in patients with type 2 diabetes and obesity through mechanisms including enhanced glucose-dependent insulin secretion, suppressed glucagon release, delayed gastric emptying, and central appetite suppression.

GLP-1 receptor agonists are highly effective medications for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to increase insulin when needed, suppress glucagon, slow down digestion, and reduce appetite. This leads to significant weight loss and better blood sugar control with a lower risk of hypoglycemia compared to older diabetes drugs. Common side effects like nausea are usually temporary and can be managed by starting with a low dose and increasing it gradually. Both injectable and oral options exist, making them accessible for many patients.

Dual and triple receptor agonists (targeting GLP-1, GIP, and/or Glucagon) provide superior weight loss and glycemic control compared to selective GLP-1 receptor agonists alone.

Newer medications that target multiple hormones (GLP-1, GIP, and Glucagon) are more effective for weight loss and blood sugar control than older GLP-1 drugs alone. Drugs like tirzepatide and retatrutide have shown remarkable results, with some patients losing over 20% of their body weight. These are taken once a week and are considered a major advancement in treating obesity and diabetes.

Discontinuation of incretin analogues (semaglutide, tirzepatide) leads to significant weight regain, with patients recovering approximately two-thirds of lost weight within one year.

If you stop taking semaglutide or tirzepatide, you will likely regain about two-thirds of the weight you lost within a year. This is because the medication's appetite-suppressing effects wear off. To maintain your weight loss, you likely need to continue the medication long-term under medical supervision.